Digital pathology added to DICOM standards

TriMed Staff | | Health Exec | EMR/EHR

The College of American Pathologists (CAP) has contributed to the expansion of the Digital Imaging and Communications in Medicine (DICOM) medical image exchange standard, Supplement 145, for the accommodation of pathology.

Supplement 145, the new standard for "Whole Microscopic Images," will enable electronic display, sharing, storage and management of larger images usually associated with pathology, and will facilitate health information interoperability of pathology medical images, various whole slide imaging equipment manufacturers, PACS and EHRs, according to CAP.

TriMed Staff

Related Content

Christmas ransomware exposed over 300K patient records to dark web
Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.